

## ORIGINAL ARTICLE

# Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer

K. Kian Ang, M.D., Ph.D., Jonathan Harris, M.S., Richard Wheeler, M.D., Randal Weber, M.D., David I. Rosenthal, M.D., Phuc Felix Nguyen-Tân, M.D., William H. Westra, M.D., Christine H. Chung, M.D., Richard C. Jordan, D.D.S., Ph.D., Charles Lu, M.D., Harold Kim, M.D., Rita Axelrod, M.D., C. Craig Silverman, M.D., Kevin P. Redmond, M.D., and Maura L. Gillison, M.D., Ph.D.

## ABSTRACT

**BACKGROUND**

Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV) are associated with favorable survival, but the independent prognostic significance of tumor HPV status remains unknown.

**METHODS**

We performed a retrospective analysis of the association between tumor HPV status and survival among patients with stage III or IV oropharyngeal squamous-cell carcinoma who were enrolled in a randomized trial comparing accelerated-fractionation radiotherapy (with acceleration by means of concomitant boost radiotherapy) with standard-fractionation radiotherapy, each combined with cisplatin therapy, in patients with squamous-cell carcinoma of the head and neck. Proportional-hazards models were used to compare the risk of death among patients with HPV-positive cancer and those with HPV-negative cancer.

**RESULTS**

The median follow-up period was 4.8 years. The 3-year rate of overall survival was similar in the group receiving accelerated-fractionation radiotherapy and the group receiving standard-fractionation radiotherapy (70.3% vs. 64.3%;  $P=0.18$ ; hazard ratio for death with accelerated-fractionation radiotherapy, 0.90; 95% confidence interval [CI], 0.72 to 1.13), as were the rates of high-grade acute and late toxic events. A total of 63.8% of patients with oropharyngeal cancer (206 of 323) had HPV-positive tumors; these patients had better 3-year rates of overall survival (82.4%, vs. 57.1% among patients with HPV-negative tumors;  $P<0.001$  by the log-rank test) and, after adjustment for age, race, tumor and nodal stage, tobacco exposure, and treatment assignment, had a 58% reduction in the risk of death (hazard ratio, 0.42; 95% CI, 0.27 to 0.66). The risk of death significantly increased with each additional pack-year of tobacco smoking. Using recursive-partitioning analysis, we classified our patients as having a low, intermediate, or high risk of death on the basis of four factors: HPV status, pack-years of tobacco smoking, tumor stage, and nodal stage.

**CONCLUSIONS**

Tumor HPV status is a strong and independent prognostic factor for survival among patients with oropharyngeal cancer. (ClinicalTrials.gov number, NCT00047008.)

From the University of Texas M.D. Anderson Cancer Center, Houston (K.K.A., R. Weber, D.I.R., C.L.); Radiation Therapy Oncology Group Statistical Center (J.H.) and Thomas Jefferson University Hospital (R.A.) — both in Philadelphia; Huntsman Cancer Institute, Salt Lake City (R. Wheeler); Centre Hospitalier de l'Université de Montréal, Montreal (P.F.N.-T.); Johns Hopkins University, Baltimore (W.H.W.); Vanderbilt University School of Medicine, Nashville (C.H.C.); University of Louisville, Louisville, KY (C.C.S.); University of California at San Francisco, San Francisco (R.C.J.); Wayne State University Medical Center, Detroit (H.K.); University of Cincinnati College of Medicine, Cincinnati (K.P.R.); and the Ohio State University Comprehensive Cancer Center, Columbus (M.L.G.). Address reprint requests to Dr. Gillison at Ohio State University, 420 W. 12th Ave., Rm. 690, Columbus, OH 43210, or at maura.gillison@osumc.edu.

This article (10.1056/NEJMoa0912217) was published on June 7, 2010, at NEJM.org.

N Engl J Med 2010;363:24-35.

Copyright © 2010 Massachusetts Medical Society.

THE MAJORITY OF PATIENTS ENROLLED IN therapeutic trials for squamous-cell carcinoma of the head and neck have oropharyngeal squamous-cell carcinoma, which in a subgroup of these patients is caused by infection with human papillomavirus (HPV).<sup>1</sup> This subgroup is defined by the presence of high-risk types of HPV in tumor cells, predominantly HPV type 16 (HPV-16). Expression of viral E6 and E7 oncoproteins that inactivate the tumor-suppressor proteins p53 and the retinoblastoma protein (pRb), respectively, is necessary for malignant behavior of these tumors.<sup>2</sup>

Several retrospective case series have shown that among patients with oropharyngeal squamous-cell carcinoma, patients with HPV-positive tumors have a better prognosis than patients with HPV-negative tumors.<sup>3</sup> Similar findings were reported in a prospective analysis of data from a clinical trial.<sup>4</sup> Because of the small sample, however, other favorable prognostic factors associated with tumor HPV status (e.g., early tumor stage or young age) could not be ruled out as an explanation for the observed difference in survival.

We sought to evaluate the effect of tumor HPV status on survival in patients with oropharyngeal squamous-cell carcinoma who were enrolled in a clinical trial of sufficient size to account for potentially confounding factors, including smoking status. Our analysis was performed within a randomized clinical trial conducted by the Radiation Therapy Oncology Group (RTOG; the RTOG 0129 study). Meta-analyses of clinical trials for patients with locally advanced squamous-cell carcinoma of the head and neck have shown that both accelerated-fractionation radiotherapy<sup>5</sup> and concurrent cisplatin-based chemotherapy improved survival as compared with standard-fractionation radiotherapy alone.<sup>6</sup> The RTOG 0129 study addressed the question of whether accelerated-fractionation radiotherapy is superior to standard-fractionation radiotherapy when each radiotherapy regimen is combined with concurrent cisplatin therapy. We report the results of this trial with an emphasis on the effect of tumor HPV status on survival among patients with oropharyngeal squamous-cell carcinoma.

## METHODS

### STUDY PROTOCOL

The RTOG 0129 study was registered with the National Cancer Institute and approved by the in-

stitutional review boards at the participating centers. All patients provided written informed consent. The authors attest to the fidelity of the article to the full protocol and statistical-analysis plan.

Eligibility criteria were the presence of untreated, pathologically confirmed, stage III or IV squamous-cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx without distant metastases (M0)<sup>7</sup>; Zubrod's performance status score of 0 or 1 (asymptomatic or symptomatic but ambulatory, respectively)<sup>8</sup>; age of 18 years or older; and adequate bone marrow, hepatic, and renal function. Lifetime tobacco exposure was determined at enrollment with the use of a standardized, self-administered questionnaire.

Patients were stratified on the basis of the tumor site (larynx vs. other), nodal stage (N0 vs. N1, N2a, or N2b vs. N2c or N3), and Zubrod's performance status score (0 vs. 1) and were randomly assigned to receive high-dose cisplatin concurrently with either accelerated-fractionation radiotherapy (with the acceleration provided by means of concomitant boost radiotherapy) or standard-fractionation radiotherapy. The accelerated-fractionation radiotherapy consisted of the delivery of 72 Gy in 42 fractions over a 6-week period, with a concomitant boost of twice-daily irradiation for 12 treatment days (as previously reported<sup>9</sup>), and standard-fractionation radiotherapy consisted of the delivery of 70 Gy in 35 fractions (i.e., 2 Gy per fraction) over a 7-week period. Intravenous cisplatin was administered at a dose of 100 mg per square meter of body-surface area on days 1 and 22 in the accelerated-fractionation radiotherapy group and on days 1, 22, and 43 in the standard-fractionation radiotherapy group.

Acute toxicity was evaluated weekly during the period of therapy according to the Common Terminology Criteria, version 2.0 ([http://ctep.info.nih.gov/protocolDevelopment/electronic\\_applications/docs/ctcv20\\_4-30-992.pdf](http://ctep.info.nih.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf)). To assess tumor status and late toxicity, according to RTOG criteria,<sup>10</sup> physical examinations and imaging studies were performed every 3 months for the first 2 years, every 6 months during years 3 through 5, and annually thereafter.

### LABORATORY STUDIES

The analysis of tumor HPV status was restricted to patients with oropharyngeal squamous-cell carcinoma because of the low prevalence of HPV among nonoropharyngeal squamous-cell carcinomas.<sup>1</sup> This post hoc subgroup analysis was not

part of the study protocol. Formalin-fixed, paraffin-embedded tumor specimens were evaluated for HPV-16 DNA with the use of the in situ hybridization-catalyzed signal-amplification method for biotinylated probes (GenPoint, Dako).<sup>11</sup> HPV-16–negative tumors were further evaluated for 12 additional oncogenic HPV types (18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) by means of a biotinylated-probe cocktail (GenPoint HPV Probe Cocktail, Dako). An HPV-positive tumor was defined as a tumor for which there was specific staining of tumor-cell nuclei for HPV in either analysis.

Tumor p16 expression was evaluated by means of immunohistochemical analysis with a mouse monoclonal antibody (MTM Laboratories) visualized with use of an autostainer (Ventana XT, Ventana) and a one-view secondary detection kit (Ventana).<sup>12</sup> Positive p16 expression was defined as strong and diffuse nuclear and cytoplasmic staining in 70% or more of the tumor cells.<sup>12</sup>

#### STUDY END POINTS

The primary end point was overall survival, defined as the time from randomization to death. Secondary end points included progression-free survival, defined as the time from randomization to death or the first documented relapse, which was categorized as local–regional disease (tumor at the primary site or regional nodes) or distant metastases. Death from the primary cancer without a documented site of recurrence or death from an unknown cause was considered death from local–regional disease. Second primary tumors were evaluated separately. Progression-free survival and its components (local–regional disease and distant metastases) were reported instead of protocol-specified secondary end points (e.g., disease-free survival) to facilitate comparison with published meta-analyses.<sup>13</sup>

#### STATISTICAL ANALYSIS

With a sample of 720 patients, the RTOG 0129 study had 80% statistical power to detect a relative reduction of 25% in the rate of death in the accelerated-fractionation radiotherapy group as compared with the standard-fractionation radiotherapy group, assuming a 2-year rate of overall survival of 45% in the standard-fractionation radiotherapy group,<sup>14,15</sup> with the use of a one-sided test at the 0.05 significance level.

Rates of overall survival and progression-free survival were estimated by means of the Kaplan–Meier method and were compared between the

two groups with the use of the log-rank test. The cumulative incidence method and Gray's test were used to estimate and compare rates of local–regional relapse, distant metastases, and second primary tumors.

Cox proportional-hazards models were used to estimate hazard ratios; multivariable models were developed by minimizing Akaike's information criterion. Cox regression was performed with the use of data on tumor HPV status and smoking status, for patients for whom these data were available. Unadjusted and adjusted hazard ratios for HPV-positive and HPV-negative status were compared between the two groups to estimate the proportion of the difference in survival that was attributable to covariates. To investigate potential bias in estimates due to missing data on HPV status, we repeated the analyses for the subgroup of patients with oropharyngeal squamous-cell carcinoma and for the entire RTOG study cohort (assuming the nonoropharyngeal squamous-cell carcinoma tumors were HPV-negative), using values imputed with the Markov chain Monte Carlo algorithm with a noninformative prior distribution (SAS/STAT software, with SAS OnlineDoc 9.1.3; SAS Institute). Twenty data sets were created, and the resulting analyses were combined per Rubin's formula.<sup>16</sup> Recursive-partitioning analysis (for censored survival data) was performed with the use of S-Tree software (<http://peace.med.yale.edu/pub/stree>) to identify the factors that were most influential for overall survival and to permit the classification of patients with oropharyngeal squamous-cell carcinoma as having a low, intermediate, or high risk of death.<sup>17</sup>

---

## RESULTS

---

#### CHARACTERISTICS OF THE PATIENTS

From July 2002 through May 2005, a total of 743 patients were enrolled in the RTOG 0129 study and randomly assigned to receive accelerated-fractionation radiotherapy or standard-fractionation radiotherapy. Analyses were restricted to the 721 patients who met the protocol study criteria (360 patients in the accelerated-fractionation radiotherapy group and the 361 patients in the standard-fractionation radiotherapy group); of the remaining 22 patients, 17 were found to be ineligible and 5 withdrew consent. The baseline characteristics of the two groups are listed in Table 1.

The majority of enrolled patients (60.1% [433 of 721]) had oropharyngeal squamous-cell carci-

noma, and HPV status was determined in 74.6% of these patients (323 of 433). Tumor specimens were not available for study in 94 patients, and tissue specimens from 16 patients did not contain tumor tissue. No significant differences in baseline characteristics, overall survival, or progression-free survival were found between patients in whom HPV status was determined and those in whom it was not, arguing against significant selection bias (see the Supplementary Appendix, available with the full text of this article at NEJM.org). HPV DNA was detected in 63.8% of patients' tumors (206 of the 323) by means of in situ hybridization, and 96.1% of the samples (198 of 206) were positive for HPV-16.

HPV-positive oropharyngeal cancer was more common among patients who had never smoked and those with a lower number of cumulative pack-years of tobacco smoking than among those with a history of heavier smoking and was also significantly associated with several favorable prognostic factors, including younger age, white race, better performance status, absence of anemia, and smaller primary tumors (Table 1). The two treatment groups were balanced with regard to tumor HPV status.

#### SURVIVAL AND TOXICITY

There were no significant differences between the accelerated-fractionation radiotherapy group and the standard-fractionation radiotherapy group with regard to the rate of death within 30 days after the start of therapy (3.3% and 1.9%, respectively;  $P=0.26$ ) or the overall rates of grade 3 or 4 acute toxic events (80.0% and 83.7%, respectively;  $P=0.21$ ) and late toxic events (25.7% and 21.1%, respectively;  $P=0.18$ ). At the data cutoff point (August 2009), 418 patients were alive. After a median follow-up of 4.8 years (range, 0.3 to 6.5), there was no significant difference in the 3-year rate of overall survival between the accelerated-fractionation radiotherapy group (70.3%; 95% confidence interval [CI], 65.6 to 75.1) and the standard-fractionation radiotherapy group (64.3%; 95% CI, 59.3 to 69.2;  $P=0.18$ ). There was a nonsignificant reduction of 10% in the risk of death for the accelerated-fractionation radiotherapy group as compared with the standard-fractionation radiotherapy group (hazard ratio, 0.90; 95% CI, 0.72 to 1.13), with a similar reduction in the subgroup of patients with HPV-positive cancer (11%; hazard ratio, 0.89; 95% CI, 0.51 to 1.55) and in the subgroup with HPV-negative cancer (9%; hazard ratio, 0.91;

95% CI, 0.69 to 1.19). The accelerated-fractionation radiotherapy group and the standard-fractionation radiotherapy group did not differ significantly with regard to progression-free survival or the pattern of relapse (see the Supplementary Appendix).

#### HPV STATUS AND SURVIVAL

For analysis of the association of tumor HPV status with survival, we combined the data for all patients with oropharyngeal squamous-cell carcinoma, since the survival rates were similar in the two treatment groups. In a Kaplan–Meier analysis, patients with HPV-positive cancer had better overall survival and progression-free survival than patients with HPV-negative cancer ( $P<0.001$  for both end points, by the log-rank test). The 3-year rates of overall survival were 82.4% (95% CI, 77.2 to 87.6) in the HPV-positive subgroup and 57.1% (95% CI, 48.1 to 66.1) in the HPV-negative subgroup (Fig. 1A), and the 3-year rates of progression-free survival were 73.7% (95% CI, 67.7 to 79.8) and 43.4% (95% CI, 34.4 to 52.4), respectively (Fig. 1B).

In the multivariable analysis, age, race, performance status, tumor stage, nodal stage, and number of pack-years of tobacco smoking were also significant determinants of overall survival and progression-free survival (Table 2). By comparing the unadjusted hazard ratios for HPV-positive versus HPV-negative tumor status (hazard ratio for death, 0.38; 95% CI, 0.26 to 0.55; and hazard ratio for relapse or death, 0.40; 95% CI, 0.29 to 0.57) (Fig. 1A and 1B) with the corresponding adjusted hazard ratios (provided below), we estimated that these factors accounted for a relative difference of approximately 9% in the rates of overall survival and progression-free survival between patients with HPV-positive and those with HPV-negative oropharyngeal squamous-cell carcinoma. Nonetheless, after this adjustment, patients with HPV-positive tumors had a 58% reduction in the risk of death as compared with patients with HPV-negative tumors (hazard ratio, 0.42; 95% CI, 0.27 to 0.66) and a 51% reduction in the risk of relapse or death (hazard ratio, 0.49; 95% CI, 0.33 to 0.74) (Table 2). After imputation for missing data, the results were similar (Table 2).

Tumors were evaluated for the expression of not only HPV but also a known biomarker of HPV-oncoprotein function, the cyclin-dependent-kinase inhibitor p16, which is induced as a consequence of pRb inactivation by the HPV E7 oncoprotein<sup>18</sup> but is minimally detectable in HPV-negative tumors because of epigenetic or genetic silencing.<sup>19</sup>

The presence of HPV DNA and the presence of p16 expression in tumors had very good agreement ( $\kappa=0.80$ ; 95% CI, 0.73 to 0.87). Using p16 expression as a stratification factor, we found differences in overall and progression-free survival that were consistent with those based on HPV status. In unadjusted analyses, the 3-year rate of overall survival was 83.6% (95% CI, 78.7 to 88.6) in the subgroup that was positive for p16 expression and 51.3% (95% CI, 41.5 to 61.0) in the subgroup that was negative for p16 expression (hazard ratio for death with positive p16 expression, 0.29; 95% CI, 0.20 to 0.43) (Fig. 1C); the 3-year rate of progression-free survival was 74.4% (95% CI, 68.5 to 80.2) and 38.4% (95% CI, 28.9 to 47.9), respectively (hazard ratio for relapse or death with positive p16 expression, 0.33; 95% CI, 0.24 to 0.46) (Fig. 1D). After adjustment for other factors, the corresponding hazard ratio for death was 0.33 (95% CI, 0.21 to 0.53), and the corresponding hazard ratio for relapse or death was 0.42 (95% CI, 0.28 to 0.64).

**Table 1. Baseline Characteristics of the Study Patients and Their Tumors, According to Patient Group.\***

Characteristic	All Study Patients		Patients with Oropharyngeal Cancer and Known Tumor HPV Status		P Value†
	Standard-Fractionation Radiotherapy and Cisplatin (N=361)	Accelerated-Fractionation Radiotherapy and Cisplatin (N=360)	HPV-Positive (N=206)	HPV-Negative (N=117)	
Treatment assignment — no. (%)					0.86
Standard-fractionation radiotherapy and cisplatin	361 (100)	0	106 (51.5)	59 (50.4)	
Accelerated-fractionation radiotherapy and cisplatin	0	360 (100)	100 (48.5)	58 (49.6)	
Age — yr					0.02
Median	56.0	55.0	53.5	57.0	
Range	34–82	26–82	31–78	37–82	
Sex — no. (%)					0.10
Male	309 (85.6)	288 (80.0)	178 (86.4)	93 (79.5)	
Female	52 (14.4)	72 (20.0)	28 (13.6)	24 (20.5)	
Race — no. (%)‡					<0.001
White	290 (80.3)	299 (83.1)	190 (92.2)	88 (75.2)	
Nonwhite	71 (19.7)	61 (16.9)	16 (7.8)	29 (24.8)	
Zubrod's performance status score — no. (%)§					0.03
0	206 (57.1)	211 (58.6)	141 (68.4)	66 (56.4)	
1	155 (42.9)	149 (41.4)	65 (31.6)	51 (43.6)	
Anemia — no. (%)¶					0.006
No	250 (69.3)	247 (68.6)	161 (78.2)	75 (64.1)	
Yes	111 (30.7)	113 (31.4)	45 (21.8)	42 (35.9)	
Primary site — no. (%)					
Oral cavity	24 (6.6)	18 (5.0)	0	0	
Oropharynx	216 (59.8)	217 (60.3)	206 (100)	117 (100)	
Hypopharynx	31 (8.6)	27 (7.5)	0	0	
Larynx	90 (24.9)	98 (27.2)	0	0	
Tumor stage — no. (%)					0.006
T2	69 (19.1)	99 (27.5)	71 (34.5)	28 (23.9)	
T3	169 (46.8)	159 (44.2)	84 (40.8)	43 (36.8)	
T4	123 (34.1)	102 (28.3)	51 (24.8)	46 (39.3)	

**Table 1. (Continued.)**

Characteristic	All Study Patients		Patients with Oropharyngeal Cancer and Known Tumor HPV Status		P Value†
	Standard-Fractionation Radiotherapy and Cisplatin (N=361)	Accelerated-Fractionation Radiotherapy and Cisplatin (N=360)	HPV-Positive (N=206)	HPV-Negative (N=117)	
Nodal stage — no. (%)					0.46
N0	67 (18.6)	69 (19.2)	15 (7.3)	9 (7.7)	
N1	54 (15.0)	53 (14.7)	22 (10.7)	24 (20.5)	
N2a	28 (7.8)	32 (8.9)	25 (12.1)	12 (10.3)	
N2b	94 (26.0)	95 (26.4)	78 (37.9)	29 (24.8)	
N2c	89 (24.7)	84 (23.3)	44 (21.4)	34 (29.1)	
N3	29 (8.0)	27 (7.5)	22 (10.7)	9 (7.7)	
AJCC stage — no. (%)					0.30
III	77 (21.3)	81 (22.5)	25 (12.1)	19 (16.2)	
IV	284 (78.7)	279 (77.5)	181 (87.9)	98 (83.8)	
Tobacco exposure — no. (%)					<0.001
Never smoked	44 (12.2)	69 (19.2)	59 (28.6)	14 (12.0)	
Former smoker	191 (52.9)	183 (50.8)	110 (53.4)	54 (46.2)	
Current smoker	83 (23.0)	68 (18.9)	24 (11.7)	32 (27.4)	
Unknown	43 (11.9)	40 (11.1)	13 (6.3)	17 (14.5)	
Tobacco-smoking history — no. of pack-years‡					<0.001
Median	33	24	12.2	36.5	
Range	0–137.5	0–152.0	0–152.0	0–96.0	
HPV status of primary oropharyngeal tumor — no./total no. (%)					
Positive	106/216 (49.1)	100/217 (46.1)	206/206 (100)	0	
Negative	59/216 (27.3)	58/217 (26.7)	0	117/117 (100)	
Unknown	51/216 (23.6)	59/217 (27.2)	0	0	
p16 Expression in oropharyngeal primary tumor — no./total no. (%)					<0.001
Positive	114/216 (52.8)	101/217 (46.5)	192/206 (93.2)	22/117 (18.8)	
Negative	48/216 (22.2)	53/217 (24.4)	7/206 (3.4)	94/117 (80.3)	
Unknown	54/216 (25.0)	63/217 (29.0)	7/206 (3.4)	1/117 (0.9)	

\* AJCC denotes the American Joint Committee on Cancer, and HPV human papillomavirus.

† P values were calculated with the use of Pearson's chi-square test for all comparisons, except age and pack-years, for which the Kolmogorov-Smirnov test was used, and tumor stage and nodal stage, for which the Kruskal-Wallis test was used.

‡ Race was self-reported.


§ Zubrod's performance status scores of 0 and 1 correspond to asymptomatic performance and symptomatic but ambulatory performance, respectively.

¶ Anemia was defined as a hemoglobin level of 13.5 g per deciliter or less for men and 12.5 g per deciliter or less for women.

|| A pack-year is defined as the equivalent of smoking one pack of cigarettes per day for 1 year. Data on pack-years were missing for 28 of the 206 patients (13.6%) with HPV-positive tumors and 29 of the 117 patients (24.8%) with HPV-negative tumors.

Tobacco smoking was also independently associated with overall survival and progression-free survival both in the subgroup of patients with oropharyngeal squamous-cell carcinoma and in

the entire study population (Table 2). The risks of death and cancer relapse or death significantly increased by 1% for each additional pack-year of tobacco smoking (Table 2), and the magnitude of



**Figure 1. Kaplan–Meier Estimates of Survival among the Study Patients with Oropharyngeal Cancer, According to Tumor HPV Status or p16-Expression Status.**

Data on overall survival and progression-free survival are shown according to stratification on the basis of tumor HPV status (Panels A and B, respectively) or p16-expression status (Panels C and D, respectively). The Kaplan–Meier curves are shown in black, and the associated 95% confidence intervals in gray. Patients with HPV-positive tumors had significantly better overall survival and progression-free survival than did patients with HPV-negative tumors ( $P<0.001$  for both comparisons by the two-sided log-rank test). The 3-year rates of overall survival were 82.4% (95% CI, 77.2 to 87.6) in the HPV-positive subgroup and 57.1% (95% CI, 48.1 to 66.1) in the HPV-negative subgroup (Panel A), and the 3-year rates of progression-free survival were 73.7% (95% CI, 67.7 to 79.8) and 43.4% (95% CI, 34.4 to 52.4), respectively (Panel B). The 3-year absolute benefit of HPV-positive status for overall survival was 25 percentage points (95% CI, 11 to 40), and the absolute benefit for progression-free survival was 30 percentage points (95% CI, 15 to 45). The results were similar with stratification according to p16-expression status. The 3-year rates of overall survival were 83.6% (95% CI, 78.7 to 88.6) in the subgroup that was positive for p16 expression and 51.3% (95% CI, 41.5 to 61.0) in the subgroup that was negative for p16 expression ( $P<0.001$ ) (Panel C), and the 3-year rates of progression-free survival were 74.4% (95% CI, 68.5 to 80.2) and 38.4% (95% CI, 28.9 to 47.9), respectively ( $P<0.001$ ) (Panel D).

the tobacco effect was similar for patients with HPV-positive cancer (hazard ratio, 1.01; 95% CI, 1.00 to 1.02) and those with HPV-negative cancer (hazard ratio, 1.01; 95% CI, 1.00 to 1.03).

In an analysis of patterns of treatment failure among patients with oropharyngeal squamous-cell carcinoma, the 3-year rate of local–regional disease, but not distant metastasis, was significantly

**Table 2. Hazard Ratios for Overall and Progression-free Survival, According to Patient Group.**

Covariate	Patients with Oropharyngeal Cancer				All Patients, with Data Imputed (N=721)	
	Complete Data (N=266)		Data Imputed (N=433)		hazard ratio (95% CI)	P value
	hazard ratio (95% CI)	P value	hazard ratio (95% CI)	P value		
<b>Overall survival</b>						
Treatment assignment (accelerated- vs. standard-fractionation radiotherapy)	1.24 (0.81–1.89)	0.32	1.09 (0.78–1.52)	0.61	0.98 (0.78–1.23)	0.87
Age (>50 yr vs. ≤50 yr)	1.62 (0.96–2.74)	0.07	1.69 (1.12–2.56)	0.01	1.35 (1.02–1.80)	0.03
Race (nonwhite vs. white)	1.57 (0.89–2.75)	0.12	2.13 (1.39–3.25)	<0.001	1.56 (1.18–2.05)	0.002
Tumor stage (T4 vs. T2–T3)	2.15 (1.40–3.29)	<0.001	2.00 (1.43–2.80)	<0.001	1.85 (1.46–2.34)	<0.001
Nodal stage (N2b–N3 vs. N0–N2a)	1.99 (1.24–3.21)	0.005	1.91 (1.30–2.79)	<0.001	1.68 (1.33–2.14)	<0.001
Pack-years of smoking (per increase of 1 yr)	1.01 (1.00–1.02)	0.003	1.01 (1.01–1.02)	<0.001	1.01 (1.00–1.01)	0.002
HPV status (positive vs. negative)	0.42 (0.27–0.66)	<0.001	0.50 (0.33–0.76)	0.002	0.41 (0.29–0.57)	<0.001
HPV status (negative vs. positive)	2.38 (1.51–3.74)	<0.001	2.00 (1.31–3.06)	0.002	2.44 (1.75–3.41)	<0.001
<b>Progression-free survival</b>						
Treatment assignment (accelerated- vs. standard-fractionation radiotherapy)	1.19 (0.81–1.73)	0.38	1.12 (0.83–1.50)	0.46	1.06 (0.86–1.31)	0.58
Age (>50 yr vs. ≤50 yr)	1.69 (1.05–2.72)	0.03	1.73 (1.20–2.50)	0.003	1.39 (1.08–1.80)	0.01
Race (nonwhite vs. white)	1.43 (0.85–2.39)	0.18	1.66 (1.13–2.44)	0.01	1.41 (1.09–1.82)	0.009
Zubrod's performance status score (1 vs. 0)	1.42 (0.97–2.09)	0.07	1.44 (1.05–1.96)	0.02	1.51 (1.22–1.88)	<0.001
Tumor stage (T4 vs. T2–T3)	1.48 (1.00–2.20)	0.05	1.32 (0.96–1.80)	0.08	1.43 (1.15–1.78)	0.001
Nodal stage (N2b–N3 vs. N0–N2a)	1.60 (1.06–2.42)	0.03	1.51 (1.09–2.10)	0.01	1.54 (1.24–1.91)	<0.001
Pack-years of smoking (per increase of 1 yr)	1.01 (1.00–1.02)	0.002	1.01 (1.00–1.01)	0.002	1.01 (1.00–1.01)	0.002
HPV status (positive vs. negative)	0.49 (0.33–0.74)	<0.001	0.53 (0.37–0.76)	<0.001	0.48 (0.36–0.65)	<0.001
HPV status (negative vs. positive)	2.02 (1.35–3.03)	<0.001	1.88 (1.31–2.70)	<0.001	2.06 (1.55–2.75)	<0.001

\* HPV denotes human papillomavirus. Estimates for each covariate have been adjusted for all other covariates listed. The data that were imputed (with the use of 20 imputations) were data on HPV status and number of pack-years. Missing HPV status was imputed for 110 patients with primary oropharyngeal cancer. Patients with a nonoropharyngeal primary site were assumed to have HPV-negative tumors. Missing number of pack-years was imputed for a total of 163 patients, 80 of whom had oropharyngeal cancer. Using the unadjusted hazard ratio for death among patients with HPV-negative (vs. HPV-positive) tumors of 2.62, we estimated that the covariates could account for 9% ( $100 \times [1 - 2.38 \div 2.62]$ ) of the different in survival between patients with HPV-positive tumors and those with HPV-negative tumors in the model with complete data and up to 25% ( $100 \times [1 - 2.00 \div 2.62]$ ) in the model with imputations. In a model with data from all patients, with HPV-positive oropharyngeal squamous-cell carcinoma as the reference group, HPV-negative oropharyngeal squamous-cell carcinoma and nonoropharyngeal squamous-cell carcinoma were associated with similar hazard ratios for death (2.29 and 2.55, respectively) and relapse or death (2.02 and 2.09, respectively).

lower for patients with HPV-positive tumors than for those with HPV-negative tumors (13.6% vs. 35.1%,  $P < 0.001$ ) (Table 3). In addition, the cumulative incidence of second primary tumors was significantly lower among patients with HPV-positive tumors, largely because of lower rates of smoking-related cancer (Table 3).

Recursive-partitioning analysis showed that the HPV status of the tumor was the major determinant of overall survival, followed by the number of pack-years of tobacco smoking ( $\leq 10$  vs.  $> 10$ ) and then nodal stage (N0 to N2a vs. N2b to N3),

for HPV-positive tumors, or tumor stage (T2 or T3 vs. T4), for HPV-negative tumors (Fig. 2A). This analysis classified patients with oropharyngeal squamous-cell carcinoma into three categories with respect to the risk of death: low risk, with a 3-year rate of overall survival of 93.0%; intermediate risk, with a 3-year rate of 70.8% (hazard ratio for the comparison with low risk, 3.54; 95% CI, 1.91 to 6.57); and high risk, with a 3-year rate of 46.2% (hazard ratio for the comparison with low risk, 7.16; 95% CI, 3.97 to 12.93) (Fig. 2B). Patients with HPV-positive tumors were considered to be



**Table 3. Survival Estimates, Causes of Death, and Patterns of Treatment Failure in Patients with Oropharyngeal Cancer, According to Tumor HPV Status.\***

Variable	HPV-Positive (N=206)	HPV-Negative (N=117)	P Value†
Overall survival at 3 yr — % (95% CI)	82.4 (77.2–87.6)	57.1 (48.1–66.1)	<0.001
Cause of death — no. of patients/total no. (%)			0.67
Primary cancer	25/50 (50.0)	29/58 (50.0)	
Second primary tumor	4/50 (8.0)	8/58 (13.8)	
Protocol treatment	1/50 (2.0)	0/58	
Nonprotocol treatment	1/50 (2.0)	1/58 (1.7)	
Cause unrelated to cancer or treatment	10/50 (20.0)	8/58 (13.8)	
Unknown	9/50 (18.0)	12/58 (20.7)	
Progression-free survival at 3 yr — % (95% CI)	73.7 (67.7–79.8)	43.4 (34.4–52.4)	<0.001
Local–regional relapse at 3 yr — % (95% CI)	13.6 (8.9–18.3)	35.1 (26.4–43.8)	<0.001
Distant metastasis at 3 yr — % (95% CI)	8.7 (4.9–12.6)	14.6 (8.1–21.1)	0.23
Type of first treatment failure — no. of patients/total no. (%)			0.55
Local–regional disease	26/66 (39.4)	33/72 (45.8)	
Distant metastasis	21/66 (31.8)	17/72 (23.6)	
Death, no documented progression	19/66 (28.8)	22/72 (30.6)	
Second primary tumor at 3 yr — % (95% CI)	5.9 (2.6–9.1)	14.6 (8.1–21.0)	0.02
Site of second primary tumor — no. of patients/total no. (%)			0.91
Head and neck	5/19 (26.3)	5/21 (23.8)	
Lung	8/19 (42.1)	9/21 (42.9)	
Prostate	2/19 (10.5)	2/21 (9.5)	
Colon	0/19	1/21 (4.8)	
Rectum	0/19	1/21 (4.8)	
Kidney	0/19	1/21 (4.8)	
Breast	0/19	1/21 (4.8)	
Skin	3/19 (15.8)	1/21 (4.8)	
Unknown	1/19 (5.3)	0/21	

\* HPV denotes human papillomavirus.

† P values were calculated with the use of Gray's test, except for overall and progression-free survival, for which the log-rank test was used, and cause of death, type of first treatment failure, and site of second primary tumor, for which Pearson's chi-square test was used. The P value for the cause of death was calculated with primary cancer, protocol treatment, and nonprotocol treatment combined. The P value for the site of a second primary tumor was calculated with head and neck cancer and lung cancer (both of which are considered to be related to smoking) combined.

at low risk, with the exception of smokers with a high nodal stage (i.e., N2b to N3), who were considered to be at intermediate risk; patients with HPV-negative tumors were considered to be at high risk, with the exception of nonsmokers with tumors of stage T2 or T3, who were considered to be at intermediate risk.

## DISCUSSION

This study provides strong evidence that tumor HPV status is an independent prognostic factor

for overall survival and progression-free survival among patients with oropharyngeal squamous-cell carcinomas, which is consistent with the hypothesis that HPV-positive and HPV-negative oropharyngeal squamous-cell carcinomas are distinct and have different causes,<sup>20</sup> risk-factor profiles,<sup>1</sup> and survival outcomes. On the basis of our data, we believe that future clinical trials should be designed specifically for patients with HPV-positive or HPV-negative squamous-cell carcinoma of the head and neck or patients who have been stratified according to HPV status. Moreover, addition-


**Figure 2. Classification of the Study Patients into Risk-of-Death Categories and Kaplan–Meier Estimates of Overall Survival According to Those Categories.**

Recursive-partitioning analysis was used to identify prognostic factors with the most influential predictive significance in a proportional-hazards model of overall survival and to classify patients into categories of low, intermediate, or high risk of death. The prognostic factors in the analysis were age, tumor stage, nodal stage, race, smoking status, HPV status, anemia status, performance status, treatment assignment, and sex. Panel A shows the resulting classifications. Panel B shows data for overall survival in the classified patients. The Kaplan–Meier curves are shown in black, and the associated 95% confidence intervals in gray. The 3-year rates of overall survival were 93.0% (95% CI, 88.3 to 97.7) in the low-risk group, 70.8% (95% CI, 60.7 to 80.8) in the intermediate-risk group, and 46.2% (95% CI, 34.7 to 57.7) in the high-risk group. Hazard ratios for death among the 266 patients for whom the risk classification could be made on the basis of the recorded data and among all 433 patients with oropharyngeal cancer (after missing data on HPV status and number of pack-years were estimated with the use of statistical imputation) were as follows: 3.54 (95% CI, 1.91 to 6.57) and 2.67 (95% CI, 1.54 to 4.62), respectively, in the intermediate-risk group versus the low-risk group; and 7.16 (95% CI, 3.97 to 12.93) and 5.23 (95% CI, 3.14 to 8.73), respectively, in the high-risk group versus the low-risk group.

al information could be gleaned from completed clinical trials, by means of reanalysis, to determine whether imbalances in tumor HPV status between treatment groups affected the outcomes and thus the therapeutic implications.

Our analysis of the association of HPV status with survival was performed in a clinical trial of locally advanced squamous-cell carcinoma of the head and neck that did not show a significant difference in overall survival between a concomitant-boost accelerated-fractionation regimen of radiotherapy and a standard-fractionation regimen, combined with concurrent, high-dose cisplatin. Therefore, either regimen could serve as the comparison for a new therapy being investigated.

We observed strong agreement between tumor HPV status, as determined by in situ hybridization, and expression of p16, an established biomarker for the function of the HPV E7 oncoprotein. Our HPV-16 in situ hybridization assay has sensitivity for single viral copies, and a positive result is strongly correlated with expression of the HPV E6 and E7 oncogenes — the standard for defining a tumor as being associated with HPV.<sup>21,22</sup> A limitation of our method is the unknown sen-



sitivity of the probe cocktail for non-HPV-16 types, which account for an estimated 5 to 10% of HPV-positive oropharyngeal squamous-cell carcinomas.<sup>23</sup> Thus, the misclassification of HPV-positive tumors as HPV-negative tumors probably explains the slightly larger reduction in the risk of death when the analysis was based on status with respect to p16 expression rather than HPV presence. A strength of the p16-expression assay is that it is not specific for HPV type, unlike the in situ

hybridization assays; therefore, p16-expression status is a very good surrogate for tumor HPV status.

The superior prognosis for HPV-positive oropharyngeal squamous-cell carcinoma, as compared with that for the HPV-negative cancer, appears to have multifactorial underpinnings. Known favorable prognostic factors associated with the HPV-positive subgroup account for approximately 10% of the detected difference in outcome. The higher survival rate among patients with HPV-positive cancer is due in part to greater local-regional control, reflecting higher intrinsic sensitivity to radiation or better radiosensitization with the use of cisplatin. Although rates of response to induction chemotherapy are higher among patients with HPV-positive tumors than among those with HPV-negative tumors,<sup>4</sup> single-agent cisplatin therapy did not appear to differentially affect the elimination of occult distant metastases. Second primary tumors, which are largely related to smoking, were less frequent among patients with HPV-positive tumors, a finding that is consistent with the lower exposure to tobacco in this subgroup. However, the rates of death from second primary tumors were similar in the HPV-positive and HPV-negative subgroups and therefore do not account for the overall differences in survival rates.

Our data clearly indicate that HPV status and status with respect to tobacco smoking are major independent prognostic factors for patients with oropharyngeal squamous-cell carcinoma, probably because they determine the molecular profile of the cancer and thus the response to therapy. Although HPV-positive oropharyngeal squamous-cell carcinoma is genetically distinct from the HPV-negative cancer with respect to patterns of loss of heterozygosity,<sup>24</sup> chromosomal abnormalities,<sup>25,26</sup> and gene-expression profiles<sup>27</sup> and is inversely correlated with biomarkers for a poor prognosis in squamous-cell carcinoma of the head and neck (e.g., p53 mutations<sup>28</sup> or expression of epidermal growth factor receptor<sup>29</sup>), no specific mechanism has been shown to explain the higher rates of response to radiation therapy and chemotherapy among patients with HPV-positive cancer.<sup>4</sup> Epidemiologic data indicate that tobacco smoking is not a strong cofactor for the development of HPV-positive oropharyngeal squamous-cell carcinoma.<sup>1</sup> Nevertheless, our data reveal that the biologic behavior of an HPV-positive tumor may be altered by tobacco use. Genetic alterations in-

duced by tobacco-associated carcinogens may render HPV-positive tumors less responsive to therapy. The likelihood of such genetic alterations appears to increase as the number of pack-years of tobacco smoking increases (Table 2). The cut-off point of 10 pack-years, which was the best predictor of survival in our recursive-partitioning analysis, may be more useful than a continuum for the design of future risk-based clinical trials but will require further validation.

The extent to which the superior survival for a patient with HPV-positive oropharyngeal squamous-cell carcinoma depends on the administered therapy is unclear. Published data indicate that tumor HPV status is a strong and consistent determinant of superior survival, regardless of treatment strategy (e.g., surgery,<sup>30</sup> radiation therapy,<sup>31,32</sup> concurrent chemoradiation therapy [in this study], or induction chemotherapy plus concurrent chemoradiation therapy<sup>4,33</sup>), with 5-year survival rates among patients with HPV-positive tumors of approximately 75 to 80%, versus 45 to 50% among patients with HPV-negative tumors.

Though no direct evidence from formal clinical trials exists to guide treatment decisions for the individual patient on the basis of tumor HPV status, this study provides a direction for future clinical research. A combination of tumor HPV status, pack-years of tobacco smoking, and cancer stage may be used to classify patients as having a low, intermediate, or high risk of death. Whether patients with HPV-positive tumors who are considered to be in the low-risk category can be spared the long-term complications of intensive, multimodal therapy without compromising their survival is now a highly relevant clinical question. In contrast, such a strategy would be inappropriate for the 36% of patients with HPV-positive tumors who are in the intermediate-risk group, for whom the 3-year rate of overall survival (71%, with an even lower rate of progression-free survival) is unacceptable. Unfortunately, patients in the high-risk group have an extremely poor prognosis and thus should be offered enrollment in trials testing more intensive investigational therapies. Should our risk model be validated in other cohorts, it will be important to incorporate tumor HPV status and tobacco exposure as nonanatomical determinants of risk classification and therapy selection for patients with oropharyngeal squamous-cell carcinoma.

The contents of this article are the sole responsibility of the authors and do not necessarily represent the official views of the NCI or NIDCR.

Supported by grants (RTOG U10 CA21661, CCOP U10 CA37422, and P01 CA06294) from the National Cancer Institute (NCI), a

grant (DE016631) from the National Institute of Dental and Craniofacial Research (NIDCR), and the Oral Cancer Foundation.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

## REFERENCES

- Gillison M, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus 16-negative head and neck cancers. *J Natl Cancer Inst* 2008;100:407-20.
- Rampias T, Sasaki C, Weinberger P, Psyri A. E6 and E7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. *J Natl Cancer Inst* 2009;101:412-23.
- Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. *Int J Cancer* 2007;121:1813-20.
- Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. *J Natl Cancer Inst* 2008;100:261-9.
- Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. *Lancet* 2006;368:843-54.
- Pignon J-P, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. *Radiother Oncol* 2009;92:4-14.
- Fleming I, Cooper J, Henson D, et al, eds. *AJCC cancer staging manual*. 5th ed. Philadelphia: Lippincott-Raven, 1997.
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982;5:649-55.
- Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. *Int J Radiat Oncol Biol Phys* 2000;48:7-16.
- Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). *Int J Radiat Oncol Biol Phys* 1995;31:1341-6.
- Huang CC, Qiu JT, Kashima ML, Kurman RJ, Wu TC. Generation of type-specific probes for the detection of single-copy human papillomavirus by a novel in situ hybridization method. *Mod Pathol* 1998;11:971-7.
- Begum S, Gillison ML, Ansari-Lari MA, Shah K, Westra WH. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. *Clin Cancer Res* 2003;9:6469-75.
- Michiels S, Le Maître A, Buyse M, et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. *Lancet Oncol* 2009;10:341-50.
- Marcial VA, Pajak TF, Mohiuddin M, et al. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck: long-term results of the Radiation Therapy Oncology Group study 81-17. *Cancer* 1990;66:1861-8.
- Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. *J Clin Oncol* 2003;21:92-8.
- Rubin D, ed. *Multiple imputations for nonresponse in surveys*. New York: Wiley, 1987.
- Analysis of censored data: survival trees. In: Zhang H, Singer B. *Recursive partitioning in the health sciences*. New York: Springer-Verlag, 1999:93-104.
- Nakao Y, Yang X, Yokoyama M, et al. Induction of p16 during immortalization by HPV16 and 18 and not during malignant transformation. *Br J Cancer* 1997;75:1410-6.
- Reed AL, Califano J, Cairns P, et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. *Cancer Res* 1996;56:3630-3.
- Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. *J Natl Cancer Inst* 2000;92:709-20.
- Shi W, Kato H, Perez-Ordóñez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in-situ hybridization for human oropharyngeal squamous carcinoma. *J Clin Oncol* 2009;27:6213-21.
- Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimens. *Int J Cancer* 2007;121:2465-72.
- Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinoma worldwide: a systematic review. *Cancer Epidemiol Biomarkers Prev* 2005;14:467-75.
- Braakhuis BJ, Snijders PJ, Keune WJ, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. *J Natl Cancer Inst* 2004;96:998-1006.
- Klussman J, Mooren J, Lehnen M, et al. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. *Clin Cancer Res* 2009;15:1779-86.
- Smeets SJ, Braakhuis BJ, Abbas S, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. *Oncogene* 2006;25:2558-64.
- Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. *Eur J Cancer* 2007;43:415-32.
- Westra WH, Taube JM, Poeta ML, Begum S, Sidransky D, Koch WM. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. *Clin Cancer Res* 2008;14:366-9.
- Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. *J Clin Oncol* 2008;26:3128-37.
- Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. *J Clin Oncol* 2006;24:5630-6.
- Lindquist D, Romanitan M, Hammarstedt L, et al. Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. *Mol Oncol* 2007;1:350-5.
- Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. *J Clin Oncol* 2009;27:1992-8.
- Settle K, Posner MR, Schumaker LM, et al. Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. *Cancer Prev Res (Phila Pa)* 2009;2:776-81.

Copyright © 2010 Massachusetts Medical Society.